GLP-1 Weight-Loss Leaders “Blow Past” Wall Street Projections in Q4 2023, Hike Prices on at Least 20 Brand Name Products in First Weeks of 2024

Big Pharma giants Eli Lilly and Novo Nordisk recently reported earnings that blew past Wall Street estimates for the fourth quarter of 2023. Both brand name companies have become leaders in what “some Wall Street analysts predict will be the best-selling class of drugs of all time,” glucagon-like peptide 1 (GLP-1) receptor agonists. Both manufacturers have continued to repeatedly hike prices on products in their portfolio to juice their rising profits – with no slowdown in sight.

Eli Lilly:

Novo Nordisk:

The expectation-besting profits come after the brand name drug makers have leveled significant price hikes in recent years – and as both companies increasingly seem like they are applying the pharmaceutical industry’s price-gouging playbook honed on diabetes drugs to these new weight loss medications.

Eli Lilly:

Novo Nordisk:

Eli Lilly & Novo Nordisk Bring Insulin Price-Gouging Playbook to New Weight Loss Meds

One of the biggest stories in the drug pricing recently has been a new “gold rush” for Big Pharma around weight loss drugs. Several Big Pharma companies have launched new products in this space or received approval to prescribe older products for this new category. It’s increasingly becoming clear, however, that Big Pharma is sizing up this new market for a business-as-usual approach to price-gouging: including targeting the U.S. for the highest prices in the world and setting egregious prices amid widespread interest and demand.

This highly anticipated category of weight loss drugs, GLP-1s, originally grew out of a category of medicines originally designed for treating diabetes. So it’s no surprise that the pharmaceutical industry appears to be bringing the same price-gouging playbook previously used on products like insulin, to this new category of medications. Two of the largest players leading the pack in terms of the development of new weight loss medications have also been two of the worst offenders when it came to insulin: Eli Lilly and Novo Nordisk.


Read more on how Eli Lilly and Novo Nordisk are applying the pharmaceutical industry’s price-gouging and patent-building playbooks honed on diabetes drugs to these new GLP-1 drugs HERE.

Read more about how Big Pharma charges the highest prices in the world for these GLP-1 drugs in the U.S. HERE.

Read more on Johnson & Johnson’s fourth quarter earnings HERE.

Read more on Pfizer and GlaxoSmithKline’s fourth quarter earnings HERE.

Read more on Merck, Bristol Myers Squibb and AbbVie’s fourth quarter earnings HERE.

And learn more about solutions to lower prescription drug prices and hold Big Pharma accountable HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.